Clinical development · November 20, 2026 · Abbott (ABT)
Abbott Begins Encantor Valve Trial
Reported company facts
Abbott’s November 19 announcement reports the start of VOYAGER CE, evaluating its investigational Encantor software-guided, balloon-expandable aortic-valve system. First enrollment occurred in Sydney, Australia.
The prospective, single-arm study plans to enroll up to 300 patients in Europe and Australia with symptomatic severe aortic stenosis. Abbott says the study will support seeking approval in those markets. The device remains investigational.
The company schedules presentation of separate early-feasibility data for November 22. That planned presentation is not a report of completed VOYAGER results.
Analysis
Our interpretation is that enrollment marks progress in clinical development, while safety, efficacy and regulatory outcomes still require evidence. A planned enrollment ceiling is not the number of patients already treated.
The announcement does not establish commercial approval or quantify future sales. Any financial assessment would require trial outcomes, regulatory decisions and commercialization details. We make no buy or sell recommendation.
Related reading
Browse the market-report index or return to the clock dashboard.